CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its candidate mRNA vaccine, SYS6016, targeting the respiratory syncytial virus (RSV).
The vaccine, SYS6016, is designed using mRNA molecules that encode the pre-fusion conformation of the full-length fusion glycoprotein (F protein) of the respiratory syncytial virus. These mRNA molecules are encapsulated in lipid nanoparticles. The vaccine is intended to prevent lower respiratory tract diseases caused by RSV infection. Preclinical studies have demonstrated that SYS6016 effectively translates into the pre-fusion conformation F protein in vivo, inducing high titer and long-lasting neutralizing antibodies. This provides robust protection against both RSV-A and RSV-B subtypes of virus strains and has shown promising safety profiles.- Flcube.com
